---

title: Angioedema
collection:
  - Allergy-Immunology
tags: ACE inhibitor

---

# Angioedema

**Definition**: self-limited, asymmetric, localized, non-pitting swelling

**Background**

-   15% of population
-   50% with urticaria
-   *Common sites:* perioribtal, lips, tongue, extremity, bowel wall
-   *Main cause of death:* Laryngeal edema (25-40% mortality if present)

## Syndromes and Specific Treatments

**Idiopathic Angioedema**

-   38% of patients with angioedema

**Allergic or IgE Mediated Angioedema**

-   Type I hypersensitivity reaction
-   Commonly from food or medications
-   *Tx:* allergen avoidance, antihistamine, H2 blockers, glucocorticoid, epinephrine for laryngeal edema

**Hereditary Angioedema**

-   C1q esterase inhibitor deficiency
-   *Triggers:* trauma (especially dental trauma), anxiety, menstruation, infection, exercise, alcohol consumption, stress
-   *Prophylaxis tx:* **danazol** better than tranexamic acid and aminocaproic acid
-   *Acute tx:*  **FFP** (or C1 inhibitor concentrate - given in Europe/Canada only)
-   Usual IgE-mediated treatment regimen ineffective except epinephrine for laryngeal edema

**ACE Inhibitor Angioedema**
-   Up to 2.2% of those taking ACE-I's
-   From elevated levels of bradykinin
-   Highest incidence during 1st month of starting medication, but can occur years after 
-   5x more common in African-Americans compared to Caucasians
-   Controversial whether patient can take ARBs (doesn’t cause elevated bradykinin) as well – some with angioedema.
-   *Tx: * discontinue medication and supportive care
-   Usual IgE-mediated treatment regimen ineffective except epinephrine for laryngeal edema

**Treatment philosophy:** 

-   Low threshold to protect airway by intubation
-   ***Pearl:*** Be sure to prescribe patients Epi-pen if discharged home
-   *Fiberoptic nasopharyngoscopy*: consider performing on all patients with voice change to look for largnyeal edema

## Admission guidelines for angioedema

([Ishoo et al., Head Neck Surg, 1999](https://www.ncbi.nlm.nih.gov/pubmed/?term=18374684))  

-   93 episodes in 80 patients (1985-95) with no deaths 
-   9.7% cases required intubation/tracheostomy
-   *Causes:* 39% from <span class="drug">ACE-I</span>
-   *Disposition:* 25% outpt, 23% floor, 53% ICU
-   ICU admissions correlated with voice change, hoarseness, dyspnea, rash 
-   Airway intervention correlated with voice change, hoarseness, dyspnea, stridor

**Proposed staging system:**

-   **Stage I:** Facial rash, facial edema, lip edema - outpatient
-   **Stage II**: Soft palate edema – outpatient or floor
-   **Stage III:** Lingual edema --&gt; ICU (7% required airway intervention)
-   **Stage IV:** Laryngeal edema –&gt; ICU (24% required airway intervention)

## References

-   [Ishoo E et al. Predicting airway risk in angioedema: Staging system based on presentation. Otolaryngol Head Neck Surg 1999; 121:263-8.](https://www.ncbi.nlm.nih.gov/pubmed/?term=18374684)
-   [Temino VM, Peebles RS. Spectrum and Treatment of Angioedema. Am J Med 2008; 121: 282-6](https://www.ncbi.nlm.nih.gov/pubmed/?term=18374684)
-   [Emedicine.com](http://emedicine.medscape.com/)
